Sun Pharma gets USFDA nod for generic drug Mesalamine extended release capsules
- Country:
- India
Sun Pharmaceutical Industries on Thursday said it has received final approval from the US health regulator for Mesalamine extended release capsules, used to treat bowel disease, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement.
As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Advertisement
ALSO READ
Indian American Akshay Bhatia claims dramatic win, books Augusta Masters spot
Indian-American Akshay Bhatia claims dramatic win, books Augusta Masters spot
Science News Roundup: Forecasts for cloudy skies cast shadow over North American solar eclipse; SpaceX launches South Korea's second spy satellite amid race with North and more
Biden seeks to cancel some interest on student loans, aiding 23 million Americans
Biden seeks to cancel some interest on student loans, aiding 23 million Americans